Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 2Gynecologic 1Genitourinary 1

Conditions

Prostatic Neoplasms 7Ovarian Neoplasms 5Breast Neoplasms 3Urinary Bladder Neoplasms 2Pancreatic Neoplasms 2Metastatic Castration Resistant Prostate Cancer 2Fallopian Tube Neoplasms 2Endometrial Neoplasms 2Colorectal Neoplasms 2Carcinoma, Transitional Cell 2Uterine Cervical Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Sarcoma 1Prostate Cancer Metastatic 1Primary Myelofibrosis 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Myeloma 1Metastatic Castration-resistant Prostate Cancer 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Lung Neoplasms 1Leukemia 1Leiomyosarcoma 1Glioblastoma 1

Interventions

pembrolizumab 33Nivolumab 15atezolizumab 9Cyclophosphamide 7Paclitaxel 6Ipilimumab 6spartalizumab 5fludarabine 5Docetaxel 5durvalumab 4avelumab 4Immune Checkpoint Inhibitors 4Carboplatin 4olaparib 3cemiplimab 3cabozantinib 3Specimen Handling 3Oxaliplatin 3Magnetic Resonance Spectroscopy 3Leucovorin 3Interleukin-2 3Gemcitabine 3Fluorouracil 3Cisplatin 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3sacituzumab govitecan 2obinutuzumab 2lenvatinib 2epacadostat 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × rucaparib × Genitourinary × Clear all
NCT03992131 2024-01-16

A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)

pharmaand GmbH

Phase 1/2 Terminated
25 enrolled 11 charts
BreastGenitourinaryGynecologic

Carcinoma, Transitional Cell, Ovarian Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡